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Abstract: The ability of drugs of abuse to cause dependence can be viewed as a form of neural plasticity. Recently, we 
have demonstrated that tumor necrosis factor- (TNF-) increases dopamine uptake and inhibits methamphetamine-
induced dependence. Moreover, we have identified a novel molecule ‘shati’ in the nucleus accumbens of mice treated 
with methamphetamine using the PCR-select cDNA subtraction method and clarified that it is involved in the develop-
ment of methamphetamine dependence: Treatment with the shati antisense oligonucleotide (shati-AS), which inhibits the 
expression of shati mRNA, enhanced the methamphetamine-induced hyperlocomotion, sensitization, and conditioned 
place preference. Further, blockage of shati mRNA by shati-AS potentiated the methamphetamine-induced increase of 
dopamine overflow and the methamphetamine-induced decrease in dopamine uptake in the nucleus accumbens. Interest-
ingly, treatment with shati-AS also inhibited expression of TNF-. Transfection of the vector containing shati cDNA into 
PC12 cells, dramatically induced the expression of shati and TNF- mRNA, accelerated dopamine uptake, and inhibited 
the methamphetamine-induced decrease in dopamine uptake. These effects were blocked by neutralizing TNF-. These 
results suggest that the functional roles of shati in methamphetamine-induced behavioral changes are mediated through 
the induction of TNF- expression which inhibits the methamphetamine-induced increase of dopamine overflow and  
decrease in dopamine uptake. 
Keywords: Shati, methamphetamine, dependence, tumor necrosis factor-, dopamine, uptake, nucleus accumbens, anti-
addictive. 
INTRODUCTION 
  Drug addiction/dependence is defined as a chronically 
relapsing disorder that is characterized by compulsive drug 
taking, inability to limit the intake, and intense drug craving. 
The positive reinforcing/rewarding effects of drugs of abuse 
depend mainly on the mesocorticolimbic dopamine system 
innervating the nucleus accumbens. It is widely accepted that 
chronic intake of drugs of abuse causes stable changes in the 
structure and function of the brain, which may be associated 
with development of drug dependence as well as the long-
lived vulnerability to relapse. Using complementary DNA 
(cDNA) microarrays, changes in the messenger RNA 
(mRNA) expression profile in relevant brain regions (e.g., 
nucleus accumbens) have been assessed following chronic 
administration of abused drugs [1-3]. Evidence from this line 
of research has implicated nuclear factor-B (NF-B) [4] and 
FosB [5] in signal transduction pathways that modulate 
behavioral effects induced by drugs and contribute to long-
term neuronal changes associated with dependence [6]. In 
order to elucidate the mechanism, caused by chronic drug 
abuse, of stable changes in the brain which play a role in  
the long-lasting behavioral abnormalities of dependent   
subjects, the candidates for drug-dependence-related genes 
whose expression was altered by repeated administration of 
 
*Address correspondence to this author at the Department of Chemical 
Pharmacology, Meijo University Graduate School of Pharmaceutical   
Sciences, 150 Yagotoyama, Tenpaku-ku, Nagoya 468-8503, Japan; 
Tel/Fax: +81-52-839-2735; E-mail: tnabeshi@ccmfs.meijo-u.ac.jp 
methamphetamine or morphine were screened by using 
cDNA microarray. We have found that tumor necrosis fac-
tor- (TNF-) and tissue plasminogen activator (tPA). Since 
there are many studies that cytokines/neurotrophic factors 
and extracellular matrix/proteases play critical role in activ-
ity-dependent synaptic plasticity and remodeling of the 
mesocorticolimbic dopaminergic system [7, 8], we focused 
these molecules. TNF- plays a neuroprotective role in 
methamphetamine-induced dependence and neurotoxicity [9] 
and reduces morphine-induced rewarding effects and behav-
ioral sensitization [10]. Furthermore, the rewarding effects 
and sensitization induced by methamphetamine and mor-
phine are attenuated by Leu-Ile, an inducer of TNF- and 
glial cell line-derived neurotrophic factor (GDNF) [10-14]. 
On the contrary, the tPA-plasmin system potentiates the re-
warding and locomotor-stimulating effects of methampheta-
mine, morphine, and nicotine by increasing release of dopa-
mine [15-17]. However, the exact neuronal circuits and mo-
lecular cascade essential for drug dependence remain un-
clear. Therefore, we attempt to explore the novel molecules 
which play more critical role in drug dependence, since the 
functions of molecules targeted by DNA microarray screen-
ing have been already well known. 
  Recently, we identified a novel molecule ‘shati’ from the 
NAc of mice treated with methamphetamine using the po-
lymerase chain reaction (PCR)-select cDNA substraction 
method, which is a differential and epochal cloning tech-
nique [18]. In this article, roles of a novel molecule ‘shati’ in Roles of a Novel Molecule ‘Shati’ in the Development of Methamphetamine  Current Neuropharmacology, 2011, Vol. 9, No. 1    105 
the development of methamphetamine-induced dependence 
are discussed. 
PSYCHOSTIMULANT-INDUCED DEPENDENCE 
  Drugs of abuse, including methamphetamine, modulate 
the activity of mesolimbic dopaminergic neurons, projecting 
from the ventral tegmental area to the nucleus accumbens 
[19-21]. The psychostimulantory effects of methampheta-
mine are associated with an increase in extracellular dopa-
mine levels in the brain, via facilitating the release of dopa-
mine from presynaptic nerve terminals and inhibition of its 
reuptake through dopamine transporter [22-24]. In rodent, 
augmentation of behavioral responses to psychostimulants is 
observed during and after their repeated administration. 
Therefore, it has been proposed that activity-dependent syn-
aptic plasticity and remodeling of the mesolimbic dopa-
minergic system may play a crucial role in drug dependence 
[25, 26]. 
IDENTIFICATION OF SHATI 
  Since we have preliminarily detected the genes affected 
by methamphetamine treatment in the nucleus accumbens of 
mouse using the PCR-select cDNA subtraction method, we 
pursued shati for intensive investigation: After administra-
tion of methamphetamine (2 mg/kg, s.c.) or saline for 6 days, 
an increase of shati mRNA production in the nucleus accum-
bens was found by 640% in methamphetamine-treated mice 
with robust behavioral sensitization compared with saline-
treated mice. The sequence of cDNA was completely 
matched to NM_001001985 of NCBI gene bank (the gene 
record was replaced by NM_001001985.2 on 10-APR-2005). 
The sequence has been identified by the Mammalian Gene 
Collection Program Team [27]. Blackshaw et al. [28] have 
demonstrated the extended cDNA sequence by serial analy-
sis of gene expression (SAGE) methods, which provides an 
unbiased and nearly comprehensive readout of gene expres-
sion, and that the gene was for one of the proteins related to 
the retina development. We have named this novel molecule 
‘shati’ after the symbol at Nagoya castle in Japan [18]. The 
sequence is translated to a protein LOC269642 (protein ID is 
NP_001001985.1 and 2; 001001985.1 was a part of 
001001985.2.). 
CHARACTERIZATION OF SHATI 
  A motif analysis revealed shati is containing the se-
quence of GCN5-related N-acetyltransferase. Docking simu-
lations with acetyl-CoA or ATP were conducted using Mo-
lecular Operating Environment software to calculate the in-
teractive potential energy. In addition, shati contains an ace-
tyl-CoA-binding or ATP-binding site, because the analysis 
showed the lowest interactive potential energy with acetyl-
CoA or ATP. Docking simulations of shati with dopamine, the 
DNA-binding site, and nuclear localization signals showed 
very high interactive potential energy or no domain. RT-PCR 
analysis revealed that shati is expressed at high levels in the 
cerebrum, cerebellum, liver, kidney, and spleen [18]. 
ROLES OF SHATI IN METHAMPHETAMINE-
INDUCED HYPERLOCOMOTION, SENSITIZATION, 
AND CONDITIONED PLACE PREFERENCE 
  Repeated methamphetamine treatment induces expres-
sion of shati mRNA dose-dependently. The expression of 
shati significantly increased 2, 6, and 24 h after the last 
methamphetamine treatment and then returned to the control 
value 1 week after the treatment. Single methamphetamine 
treatment remarkably induced the expression of shati mRNA 
in the nucleus accumbens and hippocampus. A metham-
phetamine or saline challenge on day 6 after repeated ad-
ministration of methamphetamine for 5 days remarkably 
induced the expression of shati in the frontal cortex, nucleus 
accumbens, and caudate-putamen. The increase caused by 
methamphetamine in the nucleus accumbens was inhibited 
by pretreatment with either the dopamine D1 receptor an-
tagonist R(+)-SCH23390 or the dopamine D2 receptor an-
tagonist raclopride. Shati is expressed in neuronal cells, but 
not astro glial cells, of the mouse brain. Treatment with a 
shati antisense oligonucleotide (shati-AS), which signifi-
cantly inhibits the expression of shati mRNA, enhanced 
methamphetamine-induced hyperlocomotion, sensitization, 
and conditioned place preference. Blockage of shati mRNA 
by shati-AS potentiated the methamphetamine-induced in-
crease of dopamine overflow in the nucleus accumbens and 
the methamphetamine-induced decrease in synaptosomal and 
vesicular dopamine uptake in the midbrain. These results 
suggest that ‘shati’ is involved in the development of meth-
amphetamine-induced hyperlocomotion, sensitization, and 
conditioned place preference. The functional roles of shati in 
methamphetamine-induced behavioral alterations are likely 
to be mediated by its inhibitory effects on the methampheta-
mine-induced increase of dopamine overflow in the nucleus 
accumbens and on the methamphetamine-induced decrease 
in dopamine uptake in the midbrain [18]. 
ROLES OF SHATI ON DOPAMINE UPTAKE – THE 
RELATIONSHIP SHATI AND TNF- 
  Interestingly, treatment with shati-AS also inhibits   
expression of TNF-  in vivo. To examine the relationship 
between shati and TNF-, and the precise mechanism behind 
the role of shati in dopamine uptake and the methampheta-
mine-induced decrease in dopamine uptake, we established a 
PC12 cell line which is transfected the vector containing 
shati cDNA. TNF- increased dopamine uptake via the   
mitogen-activated protein kinase pathway, and inhibited the 
methamphetamine-induced decrease in dopamine uptake in 
PC12 cells (Fig. 1). Shati was expressed in TNF--immuno- 
positive cells. Transfection of the vector containing shati 
cDNA into PC12 cells, dramatically induced the expression 
of shati and TNF- mRNA, accelerated dopamine uptake, 
and inhibited the methamphetamine-induced decrease in 
dopamine uptake (Fig. 1). These effects were blocked by 
neutralizing TNF- (Fig. 1). These results suggest that   
the functional roles of shati in methamphetamine-induced   
behavioral changes are mediated through the induction of 
TNF- expression which inhibits the methamphetamine-
induced increase of dopamine overflow and decrease in   
dopamine uptake [29] (Figs. 1 and 2). Targeting the shati-
TNF- system would provide a new therapeutic approach   
to the treatment of methamphetamine dependence [18, 29] 
(Fig. 2). 
DISCUSSION 
  As reviewed in this article, the roles of ‘shati’, which 
have been identified as a specific candidate molecule for the 
development of methamphetamine-induced dependence, 106    Current Neuropharmacology, 2011, Vol. 9, No. 1  Niwa and Nabeshima 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Roles of shati on dopamine uptake – the relationship shati and TNF-. TNF- increased dopamine uptake via the mitogen-
activated protein kinase kinase (MEK) signaling pathway in PC12 cells. The increase was antagonized by the anti-TNF- antibody (Ab) and 
soluble TNF receptor I (sRI), suggesting that TNF- certainly increases dopamine uptake in PC12 cells. Moreover, TNF- inhibited the meth-
amphetamine-induced decrease in dopamine uptake in PC12 cells. Overexpression of shati increased dopamine uptake and inhibited the 
methamphetamine-induced decrease in dopamine uptake in PC12 cells by increasing TNF- expression, since these effects were antagonized 
by anti-TNF- antibody and soluble TNF receptor I. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). The functional roles of shati in the development of methamphetamine-induced dependence. Under basal conditions, plasmalemmal 
dopamine transporter is involved in the reuptake of extracellular dopamine into the cytosol; subsequently the cytosolic dopamine is stored into 
synaptic vesicles via vesicular monoamine transporter-2. Treatment of methamphetamine inhibits dopamine uptake through dopamine transporter 
and facilitates dopamine’s release from presynaptic nerve terminals, resulting in potentiation of the methamphetamine-induced dependence. 
Methamphetamine induces shati and TNF- expression in the target neurons through the activation of dopamine receptors. TNF- induced  
by shati inhibits the methamphetamine-induced increase of dopamine overflow in the nucleus accumbens by promoting dopamine uptake  
via mitogen-activated protein kinase kinase (MEK) pathway and finally inhibits sensitization to and the rewarding effects of methamphetamine. 
Targeting the shati-TNF- system would provide a new therapeutic approach to the treatment of methamphetamine dependence. 
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were discussed. Recent evidence has demonstrated that vari-
ous cytokines and proteinases also participate to the devel-
opment and relapse of drug dependence, which may be di-
vided into two groups. Anti-addictive factors such as shati 
[18, 29], piccolo [30], TNF- [9, 10], and GDNF [8, 11-14, 
31] act to reduce the rewarding effect of drugs of abuse. Pro-
addictive factors that act to potentiate the rewarding effect of 
drugs include basic fibroblast growth factor (bFGF) [32], 
brain-derived neurotrophic factor (BDNF) [7, 33], tPA [15-
17], matrix metalloproteinase (MMP)-2 and MMP-9 [34, 
35]. These findings suggest that an imbalance between anti-
addictive and pro-addictive factors contributes to the devel-
opment and relapse of drug dependence [14, 26]. We pro-
pose that the dynamic changes in and balance of levels of 
anti-addictive and pro-addictive factors in the brain are one 
of the determinants of susceptibility to drug dependence. 
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